Literature DB >> 19844205

Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.

Luigi Gatta1, Nimish Vakil, Gioacchino Leandro, Francesco Di Mario, Dino Vaira.   

Abstract

OBJECTIVES: Eradication rates with triple therapy (TT) for Helicobacter pylori infection have declined to unacceptable levels. Sequential therapy (ST) is a novel treatment that has shown promise in several controlled trials. Our aim was to assess the efficacy of ST in adults and children compared with that of TT by performing a systematic review and meta-analysis.
METHODS: We performed an electronic search of the following: Cochrane Trial Register (until Issue 4, 2008), MEDLINE (1966 to 21 October 2008), EMBASE (1980 to 21 October 2008), and abstracts from the major US, European, and Asian gastroenterology conferences. Randomized controlled trials (RCTs) and controlled clinical trials with a parallel group design comparing the ST with a TT lasting at least 7 days were used.
RESULTS: Ten RCTs enrolled 3,006 adult patients and the odds ratio (OR) for eradication of H. pylori with ST compared with TT was 2.99 (95% confidence interval (CI): 2.47-3.62), giving a number needed to treat (NNT) of 6 (95% CI: 5-7) favoring ST. There was no publication bias. The OR for eradication with ST compared with 10-day TT was 2.92 (95% CI: 1.95-4.38), yielding an NNT of 8 (95% CI: 6-12), favoring ST. In patients with clarithromycin resistance, the OR for eradication with ST was 10.21 (95% CI: 3.01-34.58) compared with TT, but the numbers studied are small. Three RCTs enrolled 260 children and adolescents, and the OR for eradication was 1.98 (95% CI: 0.96-4.07). There was no difference in the rate of side effects between the ST and the TT (OR, 1.01; 95% CI: 0.78-1.30).
CONCLUSIONS: ST appears to be better than TT in the eradication of H. pylori. This is a promising therapy, but further trials are needed in other European countries and North America before it can be recommended as a first-line treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19844205     DOI: 10.1038/ajg.2009.555

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  91 in total

1.  First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective.

Authors:  György-Miklós Buzás
Journal:  World J Gastroenterol       Date:  2010-08-21       Impact factor: 5.742

2.  Sequential Therapy for Helicobacter Pylori Eradication: The Time is Now!

Authors:  Dino Vaira; Angelo Zullo; Cesare Hassan; Giulia Fiorini; Nimish Vakil
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

3.  Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population.

Authors:  Luigi Gatta; Francesco Di Mario; Dino Vaira; Angelo Franzé; Massimo Rugge; Alberto Pilotto; Paolo Lucarini; Maurizio Lera; Giulia Fiorini; Valentina Castelli; Enkleda Kajo; Carmelo Scarpignato
Journal:  Intern Emerg Med       Date:  2010-08-19       Impact factor: 3.397

4.  Management of Helicobacter pylori infection in Latin America: a Delphi technique-based consensus.

Authors:  Antonio Rollan; Juan Pablo Arab; M Constanza Camargo; Roberto Candia; Paul Harris; Catterina Ferreccio; Charles S Rabkin; Juan Cristóbal Gana; Pablo Cortés; Rolando Herrero; Luisa Durán; Apolinaria García; Claudio Toledo; Alberto Espino; Nicole Lustig; Alberto Sarfatis; Catalina Figueroa; Javier Torres; Arnoldo Riquelme
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

5.  Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.

Authors:  Ping-I Hsu; Feng-Woei Tsai; Sung-Shuo Kao; Wen-Hung Hsu; Jin-Shiung Cheng; Nan-Jing Peng; Kuo-Wang Tsai; Huang-Ming Hu; Yao-Kuang Wang; Seng-Kee Chuah; Angela Chen; Deng-Chyang Wu
Journal:  Am J Gastroenterol       Date:  2017-07-18       Impact factor: 10.864

6.  Empiric therapies for Helicobacter pylori infections.

Authors:  David Y Graham; Lori A Fischbach
Journal:  CMAJ       Date:  2011-02-22       Impact factor: 8.262

7.  Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication.

Authors:  Peter Malfertheiner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10       Impact factor: 46.802

8.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

9.  A comparison amongst three rapid urease tests to diagnose Helicobacter pylori infection in 375 consecutive dyspeptic.

Authors:  Dino Vaira; Luigi Gatta; Chiara Ricci; Federico Perna; Ilaria Saracino; Giulia Fiorini; Valentina Castelli; John Holton
Journal:  Intern Emerg Med       Date:  2010-02       Impact factor: 3.397

10.  Advances in gastric cancer prevention.

Authors:  Antonio Giordano; Letizia Cito
Journal:  World J Clin Oncol       Date:  2012-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.